PRQR
ProQR Therapeutics N.V. NASDAQ Listed Sep 18, 2014$1.89
+13.17%
vs $1.67
Mkt Cap $199.1M
52w Low $1.37
31.0% of range
52w High $3.05
50d MA $1.62
200d MA $1.92
P/E (TTM)
—
EV/EBITDA
—
P/B
4.0x
Debt/Equity
0.3x
ROE
—
P/FCF
-3.9x
RSI (14)
65.30
ATR (14)
$0.13
Beta
0.09
50d MA
$1.62
200d MA
$1.92
Avg Volume
576.7K
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Zernikedreef 9 · Leiden, P7 2333 Ck · NL
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | BMO | — | — | — | 1.61 | -0.6% | -0.6% | +6.2% | -2.9% | -3.6% | -5.0% | — |
| May 8, 2026 | BMO | — | — | — | 1.58 | -0.6% | +0.0% | +1.9% | -0.6% | +6.2% | -2.9% | — |
| May 7, 2026 | BMO | — | — | — | 1.72 | +0.0% | -8.1% | +0.0% | +1.9% | -0.6% | +6.2% | — |
| Mar 12, 2026 | BMO | -0.08 | -0.09 | -12.5% | 1.72 | +0.6% | +5.8% | -3.3% | +0.6% | -2.8% | -7.6% | — |
| Nov 6, 2025 | BMO | -0.10 | -0.12 | -20.0% | 2.21 | -2.7% | +0.5% | -2.7% | +0.0% | +0.0% | +0.0% | — |
| Aug 7, 2025 | BMO | -0.08 | -0.14 | -75.0% | 2.05 | +2.0% | +5.9% | -12.9% | +1.1% | +5.8% | +0.0% | — |
| May 8, 2025 | BMO | -0.09 | -0.11 | -22.2% | 1.55 | -0.6% | +3.9% | -1.2% | -3.8% | +1.3% | +5.2% | — |
| Mar 13, 2025 | BMO | -0.10 | -0.10 | +0.0% | 1.74 | +2.3% | -2.9% | +0.6% | -3.5% | -0.6% | +0.0% | — |
| Nov 7, 2024 | BMO | -0.12 | -0.11 | +8.3% | 3.57 | +3.6% | +5.6% | +5.0% | +0.5% | -0.5% | -0.3% | — |
| Aug 8, 2024 | BMO | -0.12 | -0.03 | +75.0% | 2.06 | -2.9% | -2.9% | +0.0% | +0.5% | +11.4% | -0.4% | — |
| May 9, 2024 | BMO | -0.12 | -0.10 | +16.7% | 2.00 | +0.0% | -1.0% | +0.0% | +0.5% | -4.0% | +0.5% | — |
| Mar 13, 2024 | BMO | -0.08 | -0.08 | +0.0% | 2.33 | +0.9% | -0.4% | +10.3% | -3.5% | +1.6% | -1.6% | — |
| Nov 7, 2023 | BMO | -0.06 | -0.08 | -33.3% | 1.35 | +8.1% | +0.0% | +3.0% | -2.2% | +2.9% | +5.0% | — |
| Aug 3, 2023 | BMO | -0.12 | -0.11 | +8.3% | 1.43 | +0.7% | +5.6% | -6.0% | -4.2% | +9.6% | +2.7% | — |
| May 16, 2023 | BMO | -0.12 | -0.12 | +0.0% | 1.78 | +0.0% | -1.7% | -0.6% | +8.0% | +1.6% | -2.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 9 | Chardan Capital | Maintains | Buy → Buy | — | $1.83 | $1.88 | +2.7% | +8.2% | -6.6% | -2.7% | +10.6% | +0.0% |
| Nov 4 | Chardan Capital | Maintains | Buy → Buy | — | $2.59 | $2.50 | -3.5% | -8.1% | +0.0% | -7.1% | +0.5% | -2.7% |
| Aug 8 | Chardan Capital | Maintains | Buy → Buy | — | $2.05 | $2.09 | +2.0% | +5.9% | -12.9% | +1.1% | +5.8% | +0.0% |
| Jun 27 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.16 | $2.20 | +1.9% | -5.6% | +0.0% | -1.5% | +6.0% | +2.3% |
| Jun 27 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $2.16 | $2.20 | +1.9% | -5.6% | +0.0% | -1.5% | +6.0% | +2.3% |
| May 13 | Oppenheimer | Maintains | Outperform → Outperform | — | $1.59 | $1.60 | +0.6% | -3.8% | +1.3% | +5.2% | -0.6% | +5.6% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.74 | $1.78 | +2.3% | -2.9% | +0.6% | -3.5% | -0.6% | +0.0% |
| Mar 14 | Chardan Capital | Maintains | Buy → Buy | — | $1.74 | $1.78 | +2.3% | -2.9% | +0.6% | -3.5% | -0.6% | +0.0% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.38 | $3.40 | +0.6% | -2.7% | -14.0% | -12.7% | +19.0% | -12.6% |
| Dec 12 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $3.38 | $3.40 | +0.6% | -2.7% | -14.0% | -12.7% | +19.0% | -12.6% |
| Dec 12 | Chardan Capital | Maintains | Buy → Buy | — | $3.38 | $3.40 | +0.6% | -2.7% | -14.0% | -12.7% | +19.0% | -12.6% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.57 | $3.70 | +3.6% | +5.6% | +5.0% | +0.5% | -0.5% | -0.3% |
| Oct 29 | Raymond James | Upgrade | Outperform → Strong Buy | — | $3.31 | $3.70 | +11.8% | +4.2% | +6.1% | -4.4% | +6.6% | -2.7% |
| May 10 | Chardan Capital | Maintains | Buy → Buy | — | $2.00 | $2.00 | +0.0% | -1.0% | +0.0% | +0.5% | -4.0% | +0.5% |
| May 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.00 | +0.0% | -1.0% | +0.0% | +0.5% | -4.0% | +0.5% |
| Apr 18 | Citigroup | Maintains | Neutral → Neutral | — | $1.90 | $1.94 | +2.1% | -2.1% | +7.0% | +0.5% | +1.0% | -0.5% |
| Mar 14 | Chardan Capital | Maintains | Buy → Buy | — | $2.33 | $2.35 | +0.9% | -0.4% | +10.3% | -3.5% | +1.6% | -1.6% |
| Mar 14 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $2.33 | $2.35 | +0.9% | -0.4% | +10.3% | -3.5% | +1.6% | -1.6% |
| Mar 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.33 | $2.35 | +0.9% | -0.4% | +10.3% | -3.5% | +1.6% | -1.6% |
| Nov 8 | Chardan Capital | Upgrade | Neutral → Buy | — | $1.35 | $1.46 | +8.1% | +0.0% | +3.0% | -2.2% | +2.9% | +5.0% |
| Nov 8 | Raymond James | Maintains | Outperform → Outperform | — | $1.35 | $1.46 | +8.1% | +0.0% | +3.0% | -2.2% | +2.9% | +5.0% |
| Sep 18 | Citigroup | Maintains | Buy → Buy | — | $1.61 | $1.61 | +0.0% | -4.3% | +0.0% | -3.9% | +0.0% | -0.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.51 | $1.51 | +0.0% | -6.0% | -4.2% | +9.6% | +2.7% | +0.0% |
| Aug 4 | Chardan Capital | Maintains | Neutral → Neutral | — | $1.43 | $1.44 | +0.7% | +5.6% | -6.0% | -4.2% | +9.6% | +2.7% |
| May 17 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.78 | $1.78 | +0.0% | -1.7% | -0.6% | +8.0% | +1.6% | -2.6% |
| May 17 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.78 | $1.78 | +0.0% | -1.7% | -0.6% | +8.0% | +1.6% | -2.6% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.78 | $1.78 | +0.0% | -1.7% | -0.6% | +8.0% | +1.6% | -2.6% |
| Mar 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.56 | +1.6% | -21.0% | +7.0% | +5.6% | -2.7% | +1.4% |
| Dec 23 | Raymond James | Maintains | Outperform → Outperform | — | $2.70 | $2.57 | -4.8% | +0.4% | +18.8% | -5.0% | +10.1% | +9.8% |
| Dec 22 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $1.65 | $2.72 | +64.8% | +63.6% | +0.4% | +18.8% | -5.0% | +10.1% |
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.86 | $0.87 | +0.9% | +3.5% | -2.2% | -2.3% | -2.8% | -1.1% |
| Aug 12 | Chardan Capital | Downgrade | Buy → Neutral | — | $0.81 | $0.85 | +4.3% | +5.5% | +3.5% | -2.2% | -2.3% | -2.8% |
| Aug 12 | Raymond James | Upgrade | Market Perform → Outperform | — | $0.81 | $0.85 | +4.3% | +5.5% | +3.5% | -2.2% | -2.3% | -2.8% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $0.64 | $0.65 | +0.8% | -8.9% | +1.4% | -5.2% | +5.0% | +5.4% |
| May 6 | Chardan Capital | Maintains | Buy → Buy | — | $0.67 | $0.66 | -1.5% | -4.5% | -8.9% | +1.4% | -5.2% | +5.0% |
| Apr 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $0.79 | $0.80 | +1.3% | -0.4% | -5.2% | +1.9% | +0.7% | -1.2% |
| Apr 14 | Chardan Capital | Maintains | Buy → Buy | — | $0.79 | $0.80 | +1.3% | -0.4% | -5.2% | +1.9% | +0.7% | -1.2% |
| Feb 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.36 | -2.2% | -10.1% | +0.8% | -3.2% | -1.6% | +1.7% |
| Feb 14 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $1.39 | $1.36 | -2.2% | -10.1% | +0.8% | -3.2% | -1.6% | +1.7% |
| Feb 14 | Chardan Capital | Maintains | Buy → Buy | — | $1.39 | $1.36 | -2.2% | -10.1% | +0.8% | -3.2% | -1.6% | +1.7% |
| Feb 14 | Raymond James | Downgrade | Strong Buy → Market Perform | — | $1.39 | $1.36 | -2.2% | -10.1% | +0.8% | -3.2% | -1.6% | +1.7% |
| Aug 9 | Chardan Capital | Maintains | Buy → Buy | — | $6.26 | $6.32 | +1.0% | +0.2% | -0.3% | +0.8% | +4.9% | -4.8% |
| Aug 11 | Chardan Capital | Maintains | Buy → Buy | — | $5.45 | $5.50 | +0.9% | +4.0% | -6.2% | -1.3% | +0.4% | -2.1% |
| Nov 19 | Citigroup | Maintains | Buy → Buy | — | $6.25 | $6.27 | +0.3% | +6.6% | +15.5% | +6.4% | +2.7% | -1.8% |
| Sep 26 | Leerink Swann | Maintains | Outperform → Outperform | — | $6.45 | $6.05 | -6.2% | -19.4% | -1.0% | -5.8% | +0.0% | -1.0% |
| Mar 15 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $4.69 | $4.89 | +4.3% | -0.2% | -6.4% | -6.2% | +3.9% | +1.9% |
No insider trades available.
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Privium Fund Management B.v. | 5,467,149 | $9M | Added | Mar 2026 |
| 2 | Morgan Stanley | 2,734,238 | $6M | Reduced | Dec 2025 |
| 3 | Aberdeen Group Plc | 3,316,965 | $5M | Added | Mar 2026 |
| 4 | Platinum Investment Management Ltd | 1,235,514 | $2M | — | Mar 2026 |
| 5 | Walleye Capital Llc | 1,215,058 | $2M | Added | Mar 2026 |
| 6 | Two Sigma Investments, Lp | 918,857 | $1M | Added | Mar 2026 |
| 7 | Point72 Asset Management | 755,842 | $1M | Reduced | Mar 2026 |
| 8 | Citadel Advisors Llc | 703,323 | $1M | Added | Mar 2026 |
| 9 | M28 Capital Management Lp | 599,793 | $972K | Reduced | Mar 2026 |
| 10 | Raymond James Financial Inc | 546,079 | $885K | Added | Mar 2026 |
| 11 | Monaco Asset Management Sam | 428,803 | $866K | Reduced | Dec 2025 |
| 12 | Ubs Group Ag | 305,264 | $495K | Reduced | Mar 2026 |
| 13 | Northern Trust Corp | 291,314 | $472K | Reduced | Mar 2026 |
| 14 | Jane Street Group, Llc | 160,175 | $324K | Added | Dec 2025 |
| 15 | Millennium Management | 194,246 | $315K | Reduced | Mar 2026 |
| 16 | Bank Of America Corp /de/ | 185,110 | $300K | Added | Mar 2026 |
| 17 | Bnp Paribas Financial Markets | 172,349 | $279K | Added | Mar 2026 |
| 18 | Franklin Street Advisors Inc /nc | 150,000 | $243K | — | Mar 2026 |
| 19 | Marshall Wace, Llp | 115,945 | $188K | New | Mar 2026 |
| 20 | Onedigital Investment Advisors Llc | 85,000 | $138K | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 3
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF | 28,243 | $45K | Feb 2026 |
| 2 | Small Cap Core Fund | 4,690 | $8K | Mar 2026 |
| 3 | Knights of Columbus U.S. ALL CAP INDEX FUND | 367 | $595 | Jan 2026 |
Valuation
Market Cap
$199.1M
Enterprise Value
$106.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
-0.38x
P/B
4.03x
P/S
14.81x
P/FCF
-3.85x
EV/EBITDA
—
Shares Out
105.3M
Financials (TTM)
Revenue
$13.4M
Net Income
-$45.6M
EBITDA
-$42.9M
Free Cash Flow
-$51.7M
Op Cash Flow
-$50.7M
EPS Basic
$-0.38
EPS Diluted
$-0.44
EPS Forward
$-0.52
Gross Margin
89.8%
Op Margin
-345.5%
Net Margin
-339.4%
Balance Sheet
Total Assets
$112.7M
Total Liab.
$63.4M
Total Equity
$49.4M
Cash
$92.4M
LT Debt
$0
Book Value/Sh
$0.47
Debt/Equity
0.28x
Current Ratio
3.09
Quick Ratio
3.09
Returns & Growth
ROE
—
ROA
—
ROIC
-49.8%
Rev Growth YoY
-19.2%
EPS Growth YoY
-11.8%
Price Returns
2W
-4.2%
1M
+0.6%
3M
-0.6%
6M
-32.5%
12M
-4.8%
Technicals
52W High
$3.05
52W Low
$1.37
50d MA
$1.62
200d MA
$1.92
RSI (14)
65.30
ATR (14)
$0.13
Beta
0.09
Avg Volume
577K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.63
High
$5.00
Low
$2.00
Median
$3.75
Data updated apr 26, 2026 8:50pm
· Source: financialmodelingprep.com